OncoMatch/Clinical Trials/NCT06693336
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Is NCT06693336 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies SMS001 for carcinoma, non-small-cell lung cancer (nsclc).
Treatment: SMS001 — This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IB, IIA, IIB, IIIA (N2) (AJCC 8th edition)
Stage Ib, IIa, IIb or IIIa (N2) for both dose escalation and dose confirmation (NOTE: Staging will be according to the AJCC 8th edition)
Prior therapy
Cannot have received: chemotherapy
No prior chemotherapy and/or thoracic radiation therapy
Cannot have received: thoracic radiation therapy
No prior chemotherapy and/or thoracic radiation therapy
Cannot have received: induction (neo-adjuvant) chemotherapy
Patients receiving induction (neo-adjuvant) chemotherapy and/or radiation prior to surgery
Cannot have received: induction (neo-adjuvant) radiation therapy
Patients receiving induction (neo-adjuvant) chemotherapy and/or radiation prior to surgery
Lab requirements
Blood counts
WBC > 2500/mm3; Neutrophil >1500/mm3; Hemoglobin >10 g/dL; Platelet >100,000/mm3; Normal PT/INR and PTT
Kidney function
Creatinine < 2 mg/dL (176.8 μmol/L); eGFR >60 mL/min/1.73m²; normal renal function
Liver function
AST and ALT < 2.5 x ULN; total bilirubin < 1.5 x ULN; normal liver function
Cardiac function
QTcF: males < 450 msec, females < 470 msec
Normal liver, and renal function at study entry; Laboratory requirements: WBC > 2500/mm3; Neutrophil >1500/mm3; Hemoglobin >10 g/dL; Platelet >100,000/ mm3; AST and ALT < 2.5 x ULN; Total bilirubin < 1.5 x ULN; Creatinine < 2 mg/dL (equivalent to 176.8 μmol/L); Normal PT/INR and PTT; eGFR >60mL/min/1.73m²; QT interval corrected for heart rate using Frederica's formula (QTcF): males < 450msec and females < 470msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify